ASHER CHANAN-KHAN, MD

Plain English
This study compared two treatments, zanubrutinib and acalabrutinib, for patients with chronic lymphocytic leukemia (CLL) who did not respond to previous treatments. It found that for every 10 patients treated with zanubrutinib, one disease progression was avoided, and for every 15 patients, one death was prevented, leading to cost savings of $7,335 per patient over two years. In a subgroup of high-risk patients, zanubrutinib was even more effective, avoiding one progression for every six patients and saving $11,533 per patient. Who this helps: This research benefits patients with relapsed or refractory CLL, especially those at high risk.

Plain English
This study compared two medications, zanubrutinib and ibrutinib, used to treat patients with chronic lymphocytic leukemia (CLL) who have not responded to previous treatments. It found that 8 patients need to be treated with zanubrutinib to prevent one person from experiencing disease progression or death, and it costs about $47,132 less per patient than ibrutinib. This matters because zanubrutinib not only improves patient outcomes but also saves money, making it a cost-effective option for treating this condition. Who this helps: Patients with relapsed chronic lymphocytic leukemia and their doctors.

Plain English
This study investigated the safety and effectiveness of a new drug called lisaftoclax for treating chronic lymphocytic leukemia (CLL). It involved 176 patients, and results showed that lisaftoclax had an overall response rate of 97.7% when used with another drug called acalabrutinib, and no serious side effects led to treatment discontinuation. This research is important because it demonstrates that lisaftoclax can help many patients with CLL, especially those who have had previous treatments that did not work. Who this helps: Patients with chronic lymphocytic leukemia.

Plain English
This study investigated how DNA changes, specifically methylation, affect the development of two types of diseases called Waldenström macroglobulinemia (WM) and IgM monoclonal gammopathy of undetermined significance (MGUS). Researchers examined 34 people—23 with WM, 6 with MGUS, and 5 healthy individuals—and found significant differences in DNA methylation patterns that influence various biological pathways related to cell growth and immune response. Understanding these changes is important because they reveal how DNA modifications can affect cancer development and help improve diagnosis and treatment strategies. Who this helps: This helps patients with IgM monoclonal gammopathies and their doctors.

Plain English
This study looked at how COVID-19 affects patients with multiple myeloma (MM) and AL amyloidosis (AL) by analyzing the medical records of 9,225 patients. Although the overall infection rate was low at 2%, 25% of those who got COVID-19 had severe cases, and there was a 22% death rate among hospitalized patients. Factors like recent treatment with certain antibodies and having heart or lung issues increased the chances of needing intensive care, while being in remission from MM or AL was linked to a lower risk of death. Who this helps: This research helps patients with multiple myeloma and AL amyloidosis, as well as their doctors, by identifying risks related to COVID-19.

Plain English
This study looked at how well a treatment combining daratumumab, bortezomib, and dexamethasone (D-Vd) works for patients with relapsed or refractory multiple myeloma compared to just bortezomib and dexamethasone (Vd). Researchers found that patients receiving D-Vd lived longer, with a median overall survival of 49.6 months compared to 38.5 months for those on Vd alone. Most groups studied, including older patients and those with high-risk disease, also showed improved survival with D-Vd, making it an important treatment option for these patients. Who this helps: This helps patients with relapsed or refractory multiple myeloma and their doctors.

Plain English
This study tested a new drug called lisaftoclax in patients with chronic lymphocytic leukemia (CLL), a type of blood cancer that has returned after treatment or did not respond to treatment. Out of 52 patients, 14 showed improvement in their condition, resulting in a response rate of 63.6%, and the patients started to see results after about 2 cycles of treatment. This finding is important because it suggests that lisaftoclax is safe and effective, with potential for more convenient dosing. Who this helps: This helps patients with chronic lymphocytic leukemia and their doctors.

Plain English
This study compared the safety of two drugs, acalabrutinib and ibrutinib, in treating chronic lymphocytic leukemia in patients who had already been treated before. The results showed that patients taking acalabrutinib experienced fewer side effects, like diarrhea and infections, while the side effects for those on ibrutinib, such as atrial fibrillation and high blood pressure, were significantly higher—up to four times more common in some cases. This is important because it suggests that acalabrutinib may be a safer option for these patients, helping them avoid some serious complications associated with ibrutinib. Who this helps: This helps patients with chronic lymphocytic leukemia and their doctors in choosing safer treatment options.

Plain English
This study looked at how well patients with multiple myeloma understand their treatment and the effects it has on their lives. Out of 1,324 people who viewed the survey, 959 responded, and it found that 86% of patients experienced troubling side effects, with more than half suffering from pain and weakness. Additionally, 57% reported feelings of depression, and only 35% were satisfied with how they were coping, showing a significant gap in patient well-being despite advancements in treatment. Who this helps: This helps patients with multiple myeloma, their doctors, and support networks.

Plain English
This study looked at a rare complication of multiple myeloma, where cancer cells spread outside the bone marrow and cause fluid buildup in the abdomen or around the lungs. It found that myelomatous ascites or pleural effusion happens in less than 1% of patients with multiple myeloma, and doctors can tell it apart from infections by analyzing the fluid. Understanding this helps improve diagnosis and treatment for patients facing this serious condition. Who this helps: This helps doctors and patients dealing with advanced multiple myeloma.

Plain English
This study looks at CD38, a protein found on cancerous cells in patients with chronic lymphocytic leukemia (CLL). Researchers found that higher levels of CD38 on these cells are linked to worse outcomes for patients, including shorter survival times. New drugs that target CD38 can help kill these cancer cells and may improve treatment options for patients. Who this helps: This helps patients with chronic lymphocytic leukemia.

Plain English
Researchers studied a new drug called lisaftoclax (APG-2575), which targets a specific protein called BCL-2 that helps cancer cells survive. They found that lisaftoclax can effectively kill cancer cells from patients with chronic lymphocytic leukemia, multiple myeloma, and Waldenström macroglobulinemia, showing strong anti-cancer effects in lab models, including the ability to enter cells quickly and disrupt their energy production. This matters because it offers a new treatment option for tough-to-treat blood cancers, showing promise especially when combined with other drugs. Who this helps: This helps patients with specific blood cancers looking for more effective treatment options.

Plain English
This study looked at the risks of severe COVID-19 infections and death in people with specific blood disorders. Researchers found that in one group, having a condition called clonal hematopoiesis did not increase the risk of dying from COVID-19, while another group of patients with monoclonal gammopathy of undetermined significance (MGUS) showed that 25% experienced severe infections, especially if their immune system was weak. This is important because it helps identify which patients with blood disorders are at higher risk for serious COVID-19 complications. Who this helps: Patients with monoclonal gammopathy and their doctors.

Plain English
This study looked at how well a specific treatment called allogeneic hematopoietic cell transplantation (allo-HCT) works for patients with Richter syndrome, a type of cancer that usually has a poor outlook. The analysis of data from 72 patients showed that 79% responded to the treatment, 33% achieved complete remission, and the average survival time was about 49% at one year, but 24% experienced serious complications, and 28% relapsed. This research is important because it confirms that allo-HCT can offer a significant chance of survival for patients who have a response to earlier treatments, but highlights the need for new strategies to lower the relapse risk. Who this helps: This helps patients with Richter syndrome and their doctors by providing evidence for a treatment option.

Plain English
This study looked at how radiation therapy is used to treat multiple myeloma and related conditions between 2004 and 2013. It found that only 25.4% of patients received radiation therapy as part of their initial treatment, with only 21.5% of multiple myeloma patients getting it compared to higher rates in those with specific types of tumors (69.3% for bone plasmacytomas). The use of radiation therapy has been decreasing over the years, especially among older patients, women, and racial minority groups. Who this helps: This research benefits patients with plasma cell disorders by highlighting the need for consistent treatment practices.

Plain English
This study looked at early deaths from multiple myeloma, a type of blood cancer, among nearly 91,000 patients from 1975 to 2015. The researchers found that 21% of patients died within six months of diagnosis, with the most common causes being the cancer itself, heart issues, infections, and kidney failure. Even though trends have slightly improved over recent years, early mortality remains a serious concern, highlighting the need for better care strategies. Who this helps: This helps patients with multiple myeloma and their doctors by identifying risks and improving treatment plans.

Plain English
This study looked at how the public's interest in following U.S. Public Health Departments on social media changed during the early days of the COVID-19 pandemic. After the national emergency was declared, overall social media following for these departments skyrocketed by 150%, especially in the Midwest and South, although levels remained low in major outbreak areas like New York and California. This is important because it shows that while people started paying more attention to public health information, there is still a huge opportunity for these departments to engage more effectively with the public online. Who this helps: This helps public health officials and departments better understand how to reach and inform the communities they serve.

Plain English
This study compared two drugs, acalabrutinib and ibrutinib, to see which one helps patients with chronic lymphocytic leukemia (CLL) better after they have already been treated. They found that both drugs allowed patients to live without their cancer getting worse for about 38 months, and acalabrutinib caused fewer heart-related side effects—9.4% of patients experienced these with acalabrutinib compared to 16.0% with ibrutinib. This matters because patients may tolerate acalabrutinib better and have fewer serious side effects. Who this helps: This helps CLL patients who need ongoing treatment after initial therapies.

Plain English
This study looked at a new treatment called indatuximab ravtansine combined with two medications, lenalidomide or pomalidomide, for patients with multiple myeloma that hasn't responded to other treatments. Of the patients treated with the lenalidomide combination, 71.7% saw positive responses, while 70.6% responded to the pomalidomide combination, with overall clinical benefits of 85% and 88%, respectively. This matters because it shows that this combination therapy can be effective in patients who have run out of other treatment options. Who this helps: This helps patients with relapsed or refractory multiple myeloma seeking new treatment options.

Plain English
This study looked at cancer clinical trials to see how well they included different ages and races compared to actual cancer patients. Out of 261 trials reviewed, 85% reported race, but those that didn’t had a greater age gap of almost 9 years compared to real-world patients, versus just over 5 years for trials that did report race. This matters because it highlights the need for more inclusive trials to ensure that findings apply to all patients, especially those who are often underrepresented. Who this helps: This helps patients, especially racial minorities and older adults with cancer.

Plain English
This study looked at how to manage lytic bone disease in patients with lymphoplasmacytic lymphoma (LPL), a type of cancer that can affect the bones. The researchers reported on an 81-year-old woman who had LPL along with lytic bone lesions, and she was successfully treated using a combination of chemotherapy and immunotherapy. Understanding how to treat this condition is important because it helps improve the outcomes for patients with similar cases. Who this helps: This helps patients with lymphoplasmacytic lymphoma and their doctors.

Plain English
This study looked at how quickly patients with multiple myeloma start treatment and discovered that delays are more common for women, Black patients, and those diagnosed in recent years. For example, Black patients were 21% more likely to have a delay in treatment compared to white patients. The findings highlight important inequalities in patient care that can impact outcomes, suggesting that addressing these delays could improve survival and quality of life for patients with multiple myeloma. Who this helps: These findings benefit patients and healthcare providers by identifying areas for improvement in cancer care.

Plain English
This study examined how depression and anxiety affect opioid use in 275 patients who received hematopoietic cell transplants for blood cancers. It found that patients who were both anxious and depressed were more than four times likely to receive opioids compared to those without depression or anxiety. In contrast, patients receiving a certain type of transplant had much lower chances of getting opioids, and those with lower health performance scores were more likely to get higher doses of opioids. Who this helps: This information helps doctors understand how mental health affects pain management in transplant patients.

Plain English
This study focused on a new drug delivery system using tiny particles called nanoparticles to treat a type of blood cancer known as Waldenstrom macroglobulinemia, especially in cases that are resistant to the standard drug bortezomib. The researchers found that when they used these nanoparticles to deliver both bortezomib and another drug called nutlin to cancer cells in mice, it led to significantly lower tumor growth compared to traditional methods, with better targeting to the cancer cells and less effect on healthy tissues. This matters because it can offer a more effective treatment option for patients whose cancer no longer responds to common therapies. Who this helps: Patients with bortezomib-resistant Waldenstrom macroglobulinemia.

Plain English
The HELIOS study looked at patients with a type of blood cancer called chronic lymphocytic leukemia who had not responded to previous treatments. The study found that those who received ibrutinib along with two other drugs had a much longer period without disease progression—about 65 months—compared to just 14 months for those who received a placebo. This is significant because it shows that adding ibrutinib can improve both the duration without the disease worsening and overall survival for these patients. Who this helps: This benefits patients with relapsed or refractory chronic lymphocytic leukemia and their doctors by providing a more effective treatment option.

Plain English
The HELIOS study looked at the combination of the drug ibrutinib along with bendamustine and rituximab in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had previously received treatment. The results showed that after about 34.8 months of follow-up, patients taking ibrutinib had a much longer progression-free survival rate of 68% compared to just 14% for those on the placebo, and 26.3% of patients on ibrutinib had no detectable cancer cells, compared to only 6.2% in the placebo group. This is significant as it indicates that ibrutinib can greatly improve treatment outcomes for patients with relapsed CLL/SLL. Who this helps: This helps patients with relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma.

Plain English
This study focused on a new treatment called lorvotuzumab mertansine for patients with a tough form of multiple myeloma that doesn't respond to existing therapies. Out of 37 patients, 43% experienced stable disease for an average of 15.5 months, and the treatment was generally safe with few severe side effects. This matters because it shows promise for a group of patients who have limited options for treatment. Who this helps: This helps patients with relapsed and refractory multiple myeloma.

Plain English
This study looked at using the drug obinutuzumab again in a patient with chronic lymphocytic leukemia who had already been treated with it and later had a relapse. After receiving obinutuzumab once more, the patient quickly achieved partial remission again and has maintained this improvement. This finding is important because it suggests that obinutuzumab can be an effective option for patients who need retreatment after an initial response, similar to another medication used for this condition called rituximab. Who this helps: This benefits patients with chronic lymphocytic leukemia who have relapsed after initial treatment.

Plain English
This study looked at a new treatment called indatuximab ravtansine (BT062) for patients with multiple myeloma who have not responded to other therapies. Researchers found that about 75% of patients had stable disease or better after treatment, with a median overall survival of 26.7 months. Most side effects were mild, with common issues including diarrhea and fatigue. Who this helps: This benefits patients with relapsed and refractory multiple myeloma looking for new treatment options.

Plain English
This study examined how combining a drug called daratumumab, which targets the CD38 protein, with another drug called ibrutinib, works to fight chronic lymphocytic leukemia (CLL). The researchers found that when these two drugs were used together, they significantly reduced tumor growth and improved survival rates in a model of CLL, compared to using either drug alone. For instance, the combination treatment not only increased the cancer-fighting effects but also disrupted important signaling pathways in cancer cells. Who this helps: This research benefits patients with chronic lymphocytic leukemia by potentially improving their treatment options.

Plain English
This study looked at the combination of pembrolizumab with pomalidomide and dexamethasone in patients with multiple myeloma that had returned or didn’t respond to previous treatments. The findings showed that patients taking the triple combination had a median progression-free survival of 5.6 months, compared to 8.4 months for those on pomalidomide and dexamethasone alone, indicating that the combination was less effective. Additionally, more serious side effects happened in the triple therapy group, and the study was halted because the risks overshadowed the benefits. Who this helps: This research helps patients with multiple myeloma and their doctors by identifying less effective treatment options.

Plain English
This study looked at survival trends in young patients, aged 40 and under, with multiple myeloma, especially focusing on how different racial and ethnic groups are faring. Researchers analyzed data from over 89,000 patients and found that while overall survival rates have significantly improved for young non-Hispanic white and non-Hispanic black patients, young Hispanic patients have not seen similar benefits; their survival rates for 5 years and 10 years showed no significant improvement. This matters because it highlights ongoing healthcare disparities that need to be addressed to ensure all patients have equal chances of survival. Who this helps: This helps young Hispanic patients with multiple myeloma and the healthcare providers treating them.

Plain English
This study looked at how two monoclonal antibodies, Daratumumab and Elotuzumab, were used in 91 patients with multiple myeloma over a year. It found that patients who received Daratumumab had more previous treatments than those in clinical trials, and infusion times were about 2 hours shorter than recommended guidelines. Additionally, while many patients experienced infusion-related reactions, these were mostly mild and did not lead to anyone stopping treatment, showing that real-world safety profiles can differ from trial results. Who this helps: This benefits patients with multiple myeloma and their doctors, providing important insights into treatment experiences outside of clinical trials.

Plain English
This study examined the risk of developing new cancers (called second primary malignancies, or SPMs) in survivors of chronic lymphocytic leukemia (CLL). Researchers found that from 1973 to 2015, CLL survivors had about a 20% higher risk of developing SPMs than the general population, with the risk particularly increased in older patients and those who had chemotherapy. The findings indicate that CLL survivors should have regular check-ups to monitor for new cancers, especially since the risk appears to have increased in recent years. Who this helps: This information benefits CLL survivors and their doctors by emphasizing the importance of ongoing health monitoring.

Plain English
This study looked at how patients with chronic lymphocytic leukemia (CLL) felt physically and emotionally after receiving a specific treatment: ibrutinib combined with bendamustine and rituximab. While overall patient well-being didn't change much for everyone, those with the worst fatigue and physical problems at the start saw significant improvements, with some reporting better energy and functioning levels. This matters because it shows that the treatment can really benefit those who are struggling the most with their health. Who this helps: Patients with severe fatigue and physical limitations from CLL.

Plain English
This study looked at how multiple myeloma (MM), a type of blood cancer, is diagnosed, treated, and the costs associated with care for Medicare patients from 1991 to 2010, focusing on racial differences. It found that while rates of diagnosis events increased and treatment options improved, there were significant disparities: Black patients had the highest rates of certain diagnosis events, and treatment was received more often by White patients compared to Hispanic and Asian patients. These findings highlight ongoing racial inequalities in cancer care, indicating that understanding these differences is crucial for improving outcomes for all patients. Who this helps: This research benefits patients and healthcare providers working to address racial disparities in cancer treatment.

Plain English
This study looked at the effects of mental health issues on patients with multiple myeloma, a type of cancer, and found that those with psychiatric conditions, like depression, had worse health outcomes and higher medical costs. Specifically, patients with psychiatric conditions experienced more health problems and used more healthcare services within the first six months of diagnosis, leading to costs that were significantly higher—about 75% more—compared to those without these conditions. This matters because understanding these impacts can help improve the care and support offered to multiple myeloma patients. Who this helps: This helps multiple myeloma patients, particularly those dealing with mental health issues.

Plain English
This study focused on developing new compounds based on curcumin, a substance found in turmeric, to fight cancer. The researchers created different versions of these compounds and tested them against cancer cells. They found that some compounds were very effective at slowing down cancer growth, particularly in certain types of blood cancer and colon cancer, showing stronger effects than regular curcumin while being less harmful to normal cells. Who this helps: This helps cancer patients by providing potential new treatment options.

Plain English
This study looked at how different groups of people with multiple myeloma, a type of blood cancer, are affected by recent advancements in treatment. Researchers found that while overall treatment outcomes are improving, certain groups—such as those differing in socioeconomic status, age, race, insurance coverage, and where they live—are still experiencing disparities in care and outcomes. Understanding these differences is important so that everyone can benefit from new therapies and achieve better health results. Who this helps: This helps patients with multiple myeloma, especially those from disadvantaged groups.

Plain English
Researchers studied the effects of a new treatment combining venetoclax, bortezomib, and dexamethasone on patients with relapsed or refractory multiple myeloma (MM), a type of blood cancer. Out of 66 patients, 67% responded to the treatment, with 42% showing significant improvement, and patients generally tolerated the drugs well, experiencing manageable side effects like diarrhea and fatigue. This matters because it offers a new, effective treatment option for patients who have not responded to previous therapies, potentially improving their quality of life and extending survival. Who this helps: Patients with relapsed or refractory multiple myeloma.

Plain English
This paper discusses hairy cell leukemia (HCL), a rare and slow-growing blood cancer that can cause symptoms like fatigue, weakness, and frequent infections. It highlights that classic HCL is different from a more aggressive form called hairy cell leukemia variant (HCLv), which does not respond well to standard treatments. The study found that most classic HCL patients have a specific genetic mutation (V600E) that is not present in other blood cancers, emphasizing the need to correctly identify and treat the two types. Who this helps: This information helps both patients with hairy cell leukemia and doctors who treat them.